A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults

Vaccine

Volumn 29, Issue 2, 2010, Pages 304-313

  Ledgerwood, J E ^a   Costner, P ^a   Desai, N ^a   Holman, L ^a   Enama, M E ^a   Yamshchikov, G ^a   Mulangu, S ^a   Hu, Z ^a   Andrews, C A ^a   Sheets, R A ^a   Koup, R A ^a   Roederer, M ^a   Bailer, R ^a   Mascola, J R ^a   Pau, M G ^b   Sullivan, N J ^a   Goudsmit, J ^b   Nabel, G J ^a   Graham, B S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b CRUCELL HOLLAND BV   (Netherlands)

Author keywords

Adenovirus; Ebola; Filovirus vaccine; Gene based vaccines

Indexed keywords

EBOLA RAD5 REPLICATION DEFECTIVE VACCINE; NEUTRALIZING ANTIBODY; PLACEBO; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS GLYCOPROTEIN;

ADENOVIRUS 5; ADULT; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; BODY TEMPERATURE; CELLULAR IMMUNITY; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOCRATIC REPUBLIC CONGO; DRUG DOSE ESCALATION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; EBOLA VIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FEVER; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; MALAISE; MALE; MYALGIA; NAUSEA; PAIN; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STAINING; SUDAN; SWELLING; T LYMPHOCYTE; VIRAL GENE THERAPY; VIRUS PARTICLE; VIRUS REPLICATION;

ADENOVIRUSES, HUMAN; ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CYTOKINES; DOUBLE-BLIND METHOD; EBOLA VACCINES; EBOLAVIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC VECTORS; HEMORRHAGIC FEVER, EBOLA; HUMANS; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; PLACEBOS; T-LYMPHOCYTES; VACCINES, ATTENUATED; VIRAL ENVELOPE PROTEINS; YOUNG ADULT;

EID: 78649703575     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.10.037     Document Type: Article

References (50)

1. Dessen A., Volchkov V., Dolnik O., Klenk H.D., Weissenhorn W. Crystal structure of the matrix protein VP40 from Ebola virus. EMBO J 2000, 19(Aug 15 (16)):4228-4236.
2. Cyranoski D. Ebola outbreak has experts rooting for answers. Nature 2009, 457(Jan 22 (7228)):364-365.
3. Outbreak news Ebola Reston in pigs and humans, Philippines. Wkly Epidemiol Rec 2009, 84(Feb 13 (7)):49-50.
4. Barrette R.W., Metwally S.A., Rowland J.M., Xu L., Zaki S.R., Nichol S.T., et al. Discovery of swine as a host for the Reston Ebola virus. Science 2009, 325(Jul 10 (5937)):204-206.
5. Towner J.S., Sealy T.S., Khristova M.L., Albarino C.G., Conlan S., Reeder S.A., et al. Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Med 2008, 4(11).
6. Bukreyev A., Marzi A., Feldmann F., Zhang L., Yang L., Ward J.M., et al. Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge. Virology 2009, 383(Jan 20 (2)):348-361.
7. Towner J.S., Pourrut X., Albarino C.G., Nkogue C.N., Bird B.H., Grard G., et al. Marburg virus infection detected in a common African bat. PLoS One 2007, 2(1):e764.
8. Pourrut X., Souris M., Towner J.S., Rollin P.E., Nichol S.T., Gonzalez J.P., et al. Large serological survey showing cocirculation of Ebola and Marburg viruses in Gabonese bat populations, and a high seroprevalence of both viruses in Rousettus aegyptiacus. BMC Infect Dis 2009, 9:159.
9. Leroy E.M., Kumulungui B., Pourrut X., Rouquet P., Hassanin A., Yaba P., et al. Fruit bats as reservoirs of Ebola virus. Nature 2005, 438(Dec 1 (7068)):575-576.
10. Towner J.S., Amman B.R., Sealy T.K., Carroll S.A., Comer J.A., Kemp A., et al. Isolation of genetically diverse Marburg viruses from Egyptian fruit bats. PLoS Pathog 2009, 5(July (7)):e1000536.
11. Geisbert T.W., Jahrling P.B. Exotic emerging viral diseases: progress and challenges. Nat Med 2004, 10(Dec (Suppl 12)):S110-S121.
12. Hensley L.E., Jones S.M., Feldmann H., Jahrling P.B., Geisbert T.W. Ebola and Marburg viruses: pathogenesis and development of countermeasures. Curr Mol Med 2005, 5(Dec (8)):761-772.
13. Bausch D.G., Feldmann H., Geisbert T.W., Bray M., Sprecher A.G., Boumandouki P., et al. Outbreaks of filovirus hemorrhagic fever: time to refocus on the patient. J Infect Dis 2007, 196:S136-S141.
14. Geisbert T.W., Lee A.C., Robbins M., Geisbert J.B., Honko A.N., Sood V., et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 2010, 375(May (9729)):1896-1905.
15. Sullivan N.J., Geisbert T.W., Geisbert J.B., Shedlock D.J., Xu L., Lamoreaux L., et al. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med 2006, 3(Jun (6)):e177.
16. Sullivan N.J., Geisbert T.W., Geisbert J.B., Xu L., Yang Z.Y., Roederer M., et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 2003, 424(6949):681-684.
17. Sullivan N.J., Sanchez A., Rollin P.E., Yang Z.Y., Nabel G.J. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000, 408(6812):605-609.
18. Bukreyev A., Rollin P.E., Tate M.K., Yang L., Zaki S.R., Shieh W.J., et al. Successful topical respiratory tract immunization of primates against Ebola virus. J Virol 2007, 81(Jun (12)):6379-6388.
19. Warfield K.L., Bosio C.M., Welcher B.C., Deal E.M., Mohamadzadeh M., Schmaljohn A., et al. Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci U S A 2003, 100(Dec 23 (26)):15889-15894.
20. Geisbert T., Daddario K.M., Lewis M.G., Geisbert J., Grolla A., Leung A., et al. Vesicular stomatitis virus-based Ebola vaccine is well tolerated and protects immunocompromised nonhuman primates. PLoS Med 2008, 4(11).
21. Hensley L.E., Mulangu S., Asiedu C., Johnson J., Honko A.N., Stanley D., et al. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species. PLoS Pathog 2010, 6(May (5)):e1000904.
22. Martin J.E., Sullivan N.J., Enama M.E., Gordon I.J., Roederer M., Koup R.A., et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol 2006, 13(Nov (11)):1267-1277.
23. Priddy F.H., Brown D., Kublin J., Monahan K., Wright D.P., Lalezari J., et al. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis 2008, 46(Jun 1 (11)):1769-1781.
24. Graham B.S., Koup R.A., Roederer M., Bailer R.T., Enama M.E., Moodie Z., et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 2006, 194(Dec 15 (12)):1650-1660.
25. Koup R.A., Lamoreaux L., Zarkowsky D., Bailer R.T., King C.R., Gall J.G.D., et al. Replication-defective adenovirus vectors with multiple deletions do not induce measurable vector-specific T cells in human trials. J Virol 2009, 83(June 15 (12)):6318-6322.
26. Sprangers M.C., Lakhai W., Koudstaal W., Verhoeven M., Koel B.F., Vogels R., et al. Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol 2003, 41(Nov (11)):5046-5052.
27. Shoenfeld Y., Blank M., Krause I. The relationship of antiphospholipid antibodies to infections-do they bind to infecting agents or may they even be induced by them?. Clin Exp Rheumatol 2000, 18(Jul-Aug (4)):431-432.
28. Jaeger U., Kapiotis S., Pabinger I., Puchhammer E., Kyrle P.A., Lechner K. Transient lupus anticoagulant associated with hypoprothrombinemia and factor XII deficiency following adenovirus infection. Ann Hematol 1993, 67(Aug (2)):95-99.
29. Malaeb B.S., Gardner T.A., Margulis V., Yang L., Gillenwater J.Y., Chung L.W., et al. Elevated activated partial thromboplastin time during administration of first-generation adenoviral vectors for gene therapy for prostate cancer: identification of lupus anticoagulants. Urology 2005, 66(Oct (4)):830-834.
30. Cervera R., Asherson R.A., Acevedo M.L., Gomez-Puerta J.A., Espinosa G., De La Red G., et al. Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients. Ann Rheum Dis 2004, 63(Oct (10)):1312-1317.
31. Catanzaro A.T., Koup R.A., Roederer M., Bailer R.T., Enama M.E., Moodie Z., et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 2006, 194(Dec 15 (12)):1638-1649.
32. Sheets R.L., Stein J., Bailer R.T., Koup R.A., Andrews C., Nason M., et al. Biodistribution and toxicological safety of adenovirus type 5 and type 35 vectored vaccines against human immunodeficiency virus-1 (HIV-1), Ebola, or Marburg are similar despite differing adenovirus serotype vector, manufacturer's construct, or gene inserts. J Immunotoxicol 2008, 5(Jul (3)):315-335.
33. Sullivan N.J., Sanchez A., Rollin P.E., Yang Z.Y., Nabel G.J. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000, 408(Nov 30 (6812)):605-609.
34. Sullivan N.J., Martin J.E., Graham B.S., Nabel G.J. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol 2009, 7(May (5)):393-400.
35. Shiver J.W., Emini E.A. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med 2004, 55:355-372.
36. Shiver J.W., Fu T.M., Chen L., Casimiro D.R., Davies M.E., Evans R.K., et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002, 415(Jan 17 (6869)):331-335.
37. Casimiro D.R., Tang A., Chen L., Fu T.M., Evans R.K., Davies M.E., et al. Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 2003, 77(Jul (13)):7663-7668.
38. Harvey B.G., Maroni J., O'Donoghue K.A., Chu K.W., Muscat J.C., Pippo A.L., et al. Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions. Hum Gene Ther 2002, 13(Jan 1 (1)):15-63.
39. Barouch D.H., Liu J., Lynch D.M., O'Brien K.L., La Porte A., Simmons N.L., et al. Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys. J Virol 2009, 83(Sep (18)):9584-9590.
40. Barefoot B., Thornburg N.J., Barouch D.H., Yu J.S., Sample C., Johnston R.E., et al. Comparison of multiple vaccine vectors in a single heterologous prime-boost trial. Vaccine 2008, 26(Nov 11 (48)):6108-6118.
41. Zubkova I., Choi Y.H., Chang E., Pirollo K., Uren T., Watanabe H., et al. T-cell vaccines that elicit effective immune responses against HCV in chimpanzees may create greater immune pressure for viral mutation. Vaccine 2009, 27(Apr 28 (19)):2594-2602.
42. Barouch D.H., Nabel G.J. Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum Gene Ther 2005, 16(Feb (2)):149-156.
43. Buchbinder S.P., Mehrotra D.V., Duerr A., Fitzgerald D.W., Mogg R., Li D., et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008, 372(Nov 29 (9653)):1881-1893.
44. McElrath M.J., De Rosa S.C., Moodie Z., Dubey S., Kierstead L., Janes H., et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008, 372(Nov 29 (9653)):1894-1905.
45. O'Brien K.L., Liu J., King S.L., Sun Y.H., Schmitz J.E., Lifton M.A., et al. Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nat Med 2009, 15(Aug (8)):873-875.
46. Koup R.A., Lamoreaux L., Zarkowsky D., Bailer R.T., King C.R., Gall J.G., et al. Multiply-deleted replication-defective adenovirus vectors do not induce measurable vector-specific T cells in human trials. J Virol 2009, [Apr 1].
47. Casimiro D.R., Chen L., Fu T.M., Evans R.K., Caulfield M.J., Davies M.E., et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 2003, 77(Jun (11)):6305-6313.
48. Koup RA, Roederer M, Lamoreaux L, Fischer J, Novik L, Nason MC, et al. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS One 5(2):e9015.
49. ClinicalTrials.gov. ; 2008. http://clinicaltrials.gov/.
50. ClinicalTrials.gov. ; 2009. http://clinicaltrials.gov/.